Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs18. March 2021|In Portfolio News|By eazee-designstudio Immatics announced a clinical data update from the dose escalation cohorts of the company’s ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T). PrevNext
